Research graph
References from Three Paths to Better Tyrosine Kinase Inhibition Behind the Blood-Brain Barrier in Treating Chronic Myelogenous Leukemia and Glioblastoma with Imatinib. Local targets link to admitted publications; unresolved targets remain external evidence.
Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate
10.1111/j.1445-5994.2009.01947.x · 2009 · External reference
Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report
10.1007/s11060-007-9352-0 · 2007 · External reference
Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid
10.1046/j.1365-2141.2002.03881.x · 2002 · External reference
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588
10.1007/s00280-003-0741-6 · 2004 · External reference
Gleevec does not cross blood-brain barrier
10.1016/s1470-2045(03)01050-7 · 2003 · External reference
Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar
10.1007/s11095-007-9278-4 · 2007 · External reference
Current status of clinical trials for glioblastoma
10.2174/157488706778250140 · 2006 · External reference
Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy
10.1080/02688690903158809 · 2009 · External reference
Recent advances in blood-brain barrier disruption as a CNS delivery strategy
10.1208/s12248-008-9018-7 · 2008 · External reference
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
10.1002/cncr.24213 · 2009 · External reference
Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth
10.1158/1078-0432.ccr-08-1316 · 2009 · External reference
MIR-451 and imatinib mesylate inhibit tumor growth of glioblastoma stem cells
10.1016/j.bbrc.2008.08.107 · 2008 · External reference
Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma
2008 · External reference
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas
10.1007/s11060-007-9408-1 · 2007 · External reference
A rapid assay for drug sensitivity of glioblastoma stem cells
10.1016/j.bbrc.2007.05.020 · 2007 · External reference
Coexpression of c-erbB 1–4 receptor proteins in human glioblastomas. An immunohistochemical study
2007 · External reference
Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy
10.1007/s10571-009-9366-6 · 2009 · External reference
In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation
2009 · External reference
Improving the prognosis for patients with glioblastoma: the rationale for targeting Src
10.1007/s11060-009-9916-2 · 2009 · External reference
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy
10.1038/nbt.1513 · 2009 · External reference
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
10.1158/1535-7163.mct-08-0669 · 2009 · External reference
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
10.1038/leu.2009.111 · 2009 · External reference
Reciprocal regulation of Abl and receptor tyrosine kinases
10.1016/j.cellsig.2009.03.003 · 2009 · External reference
Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia
10.1053/j.seminhematol.2009.01.009 · 2009 · External reference
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
10.1182/blood-2008-02-140665 · 2008 · External reference
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
10.1200/jco.2007.14.3339 · 2009 · External reference
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value
10.1038/leu.2009.156 · 2009 · External reference
Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib
10.1002/pbc.22083 · 2009 · External reference
Noninvasive imaging of αVβ3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib
10.1158/0008-5472.can-08-3390 · 2009 · External reference
Using blood brain barrier disruption by methamphetamine for drug delivery
10.1007/s11060-007-9389-0 · 2007 · External reference
Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma
10.1007/s11060-009-9863-y · 2009 · External reference
Initiation into methamphetamine use: qualitative findings from an exploration of first time use among a group of New Zealand users
10.1080/02791072.2009.10400670 · 2009 · External reference
A review of the clinical pharmacology of methamphetamine
10.1111/j.1360-0443.2009.02564.x · 2009 · External reference
Pathogenesis of hepatitis C virus co-infection in the brains of patients infected with HIV
10.1086/519285 · 2007 · External reference
Acceleration of HIV dementia with methamphetamine and cocaine
10.1080/135502801300069737 · 2001 · External reference
Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse
2007 · External reference
High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users
10.1093/jat/30.4.232 · 2006 · External reference
Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication
10.1093/jat/27.3.135 · 2003 · External reference
Anesthetic pentobarbital inhibits proliferation and migration of malignant glioma cells
10.1016/j.canlet.2009.02.055 · 2009 · External reference
The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification
10.1111/j.1440-1789.2008.00911.x · 2008 · External reference
New directions in the treatment of imatinib failure and/or resistance
10.1053/j.seminhematol.2009.01.011 · 2009 · External reference
